Valeant Pharmaceuticals Intl Inc (VRX) : Gateway Advisory added new position in Valeant Pharmaceuticals Intl Inc during the most recent quarter end. The investment management firm now holds 13,000 shares of Valeant Pharmaceuticals Intl Inc which is valued at $288,340 , the company said in a statement filed on Oct 14, 2016 with the SEC.Valeant Pharmaceuticals Intl Inc makes up approximately 0.10% of Gateway Advisory’s portfolio.
Other Hedge Funds, Including , Integrated Investment Consultants boosted its stake in VRX in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 1,000 shares of Valeant Pharmaceuticals Intl Inc which is valued at $22,180. Valeant Pharmaceuticals Intl Inc makes up approx 0.01% of Integrated Investment Consultants’s portfolio. Carl Domino Inc added VRX to its portfolio by purchasing 9,000 company shares during the most recent quarter which is valued at $206,460. Valeant Pharmaceuticals Intl Inc makes up approx 0.20% of Carl Domino Inc’s portfolio.Hexavest boosted its stake in VRX in the latest quarter, The investment management firm added 1,973,087 additional shares and now holds a total of 3,765,875 shares of Valeant Pharmaceuticals Intl Inc which is valued at $86,389,173. Valeant Pharmaceuticals Intl Inc makes up approx 1.57% of Hexavest’s portfolio.
Valeant Pharmaceuticals Intl Inc closed down -0.59 points or -2.59% at $22.18 with 1,18,31,367 shares getting traded on Friday. Post opening the session at $22.85, the shares hit an intraday low of $22.12 and an intraday high of $23.08 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $1.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $1.48. The company had revenue of $2420.20 million for the quarter, compared to analysts expectations of $2451.77 million. The company’s revenue was down -11.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $2.14 EPS.
Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Shares were Reiterated by Deutsche Bank on Oct 14, 2016 to “Hold” and Lowered the Price Target to $ 29 from a previous price target of $30 .Shares were Reiterated by RBC Capital Mkts on Oct 12, 2016 to “Sector Perform” and Lowered the Price Target to $ 35 from a previous price target of $36 .Deutsche Bank Resumed Valeant Pharmaceuticals Intl Inc on Sep 20, 2016 to “Hold”, Price Target of the shares are set at $30.
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.